Seaport Therapeutics

We’re looking forward to the 44th Annual J.P. Morgan Healthcare Conference, where our Co-founder and Chief Executive Officer, Daphne Zohar, will present on Monday, January 12, 2026, at 9:30 AM PST.   For the Q&A portion of the presentation, Daphne will be joined by Steven Paul, M.D., Co-founder & Chair & Michael C. Chen, Ph.D., Co-founder & Chief Scientific Officer. #JPM26 Read the press release: https://lnkd.in/eEd2f-z6

As 2025 comes to a close, we’re reflecting on a year of meaningful progress at Seaport. From advancing two programs further into the clinic — with the initiations of the phase 2b BUOY-1 study of GlyphAllo™ in major depressive disorder with our without anxious distress and a phase 1 study of GlyphAgo™ for the treatment of generalized anxiety disorder — to strengthening connections through company events and celebrating shared milestones, none of this would be possible without our incredible team’s dedication to serving those living with #neuropsychiatric conditions.   We look forward to another year with more time together bringing out the best in each other and continued progress toward delivering new medicines that have the potential to make a difference in the lives of people dealing with #depression and #anxiety.    Wishing you a #HappyHolidays from all of us at Seaport!

A candid convo between two biotech leaders: our CEO Daphne Zohar chats with Kate Haviland (former Blueprint Medicines CEO) about building & leading high performing teams, having a “truth-seeking” mentality, small biotechs successfully commercializing medicines & the path to Blueprint's $9B+ acquisition, plus perspectives on the biotech industry today. Here’s a link to the full BiotechTV episode: https://bit.ly/48V8h0Q

Listen today at 10:00 AM EST for a company presentation from our Chief Financial Officer, Lauren White, and Chief Scientific Officer, Michael C. Chen, PhD, at the RBC Capital Markets Healthcare Private Company Conference.    Tune in live: https://lnkd.in/eMNmbuZp In case you miss it, a replay will be available on our website here: https://lnkd.in/eMNriPaf   Members of our team will also participate in one-on-one meetings during the conference.

Today we announced the presentation of data that further validate the ability of our proprietary Glyph™ platform to enhance oral bioavailability and successfully be applied to another class of clinically validated molecules previously held back by poor drug-like properties.   The findings, presented at the American Epilepsy Society (#AES2025) Annual Meeting, show the application of Glyph to create an oral prodrug of cannabidiol (CBD), a clinically validated anti-epileptic drug constrained by low oral bioavailability, hepatotoxicity and gastrointestinal side effects. The Glyphed version of CBD enhanced pharmacokinetic properties and significantly improved anti-seizure activity at lower CBD doses. In the head-to-head comparison, GlyphCBD™ (SPT-310 or Glyph Cannabidiol) was shown to prevent seizures at a median effective CBD dose three times lower than a non-Glyph oral CBD formulation.   This additional evidence supports the broad applicability of our Glyph platform to improve oral drug delivery across a wide range of therapeutic molecules, underscoring Glyph’s potential to create better medicines across multiple indications.   Read the press release: https://lnkd.in/eqR8Pdr4 View the poster: https://lnkd.in/e73nzZ-2

We’re pleased to share that members of our management team will be presenting at the 2025 RBC Capital Markets Healthcare Private Company Conference on Thursday, December 11, at 10:00 AM EST. Members of the team will also participate in one-on-one meetings while at the conference.    Read the press release: https://lnkd.in/eSXEuAQP   The live and archived webcast will available be under the events section of our website: https://lnkd.in/eMNriPaf

Recently, members of our team participated in the American Foundation for Suicide Prevention’s (AFSP) annual “Out of the Darkness” walk in Boston to raise awareness for suicide prevention.   Our Chief Medical Officer and President of Clinical Development, Antony Loebel (Tony), serves on the AFSP’s board where he brings his industry and clinical experience together to dedicate his time to support the organization’s mission to save lives and bring hope to those affected by suicide.    The link between suicide and major depressive disorder (#MDD) is stark — suicide risk in people with MDD is ~20x that of the general population, and in 2021, suicide ranked in the top three leading causes of death in people ages 10-34, underscoring the high unmet need in neuropsychiatry.    Tony’s work closely aligns with our service value at Seaport – we exist to serve individuals with #mentalhealth conditions and deliver potentially life-changing medicines for those living with #depression and #anxiety. We will continue to raise awareness and advocate for suicide prevention.

Our Founder and CEO Daphne Zohar recently joined John Stanford on the Making Medicine Podcast for a wide-ranging conversation on the current policy environment, the state of the biotech ecosystem, her personal journey in biotech, our mission at Seaport Therapeutics, and Boston as a biotech hub. Daphne also shares a glimpse into her advocacy work on Biotechnology Innovation Organization’s Exec Committee, No Patient Left Behind, as well as the community she’s helped build with Biotech Hangout (shout-outs to her co-founders and co-hosts, Brad Loncar and Chris Garabedian, and many others). CC: MassBio Incubate Coalition   Watch the full episode: https://lnkd.in/e3ZZ-rcj

Wishing you a #HappyThanksgiving from our Seaport team! Ahead of the holiday, members of our team came together to assemble care packages for Rosie’s Place - a women’s shelter in Boston that provides emergency shelter and meals to women in need. We also took time to enjoy each other’s company with a Thanksgiving-themed luncheon and reflect on what we’re grateful for. Coming together and giving back remind us why we’re here at Seaport - to serve those living with #mentalhealth conditions like #depression and #anxiety.